On the public citation graph

Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes

0 signed · 187 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

1 of the 42 references listed on this page is in the Retraction Watch database as retracted (export 2026-11-18): 10.1210/jc.2014-2739 (notice 2015-05-01).

Dataset join, best-effort; this page does not check the publisher record. Retraction Watch data via Crossref Labs, used with credit; OpenCitations Index (CC0) and Meta (CC BY 4.0); dataset doi:10.7910/DVN/WT8VOA (CC BY 4.0).

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2015.5370openalex-snapshot
Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1002/hep.20466openalex-snapshot
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
inferredcites →https://doi.org/10.1002/hep.23116openalex-snapshot
Importance of Changes in Adipose Tissue Insulin Resistance to Histological Response During Thiazolidinedione Treatment of Patients with Nonalcoholic Steatohepatitis†
inferredcites →https://doi.org/10.1002/hep.23280openalex-snapshot
Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic, and Clinical Implications
inferredcites →https://doi.org/10.1002/hep.23594openalex-snapshot
Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection
inferredcites →https://doi.org/10.1002/hep.23719openalex-snapshot
Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis
inferredcites →https://doi.org/10.1002/hep.24376openalex-snapshot
Endpoints and clinical trial design for nonalcoholic steatohepatitis
inferredcites →https://doi.org/10.1002/hep.24483openalex-snapshot
Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis
inferredcites →https://doi.org/10.1002/hep.25539openalex-snapshot
Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1002/hep.26988openalex-snapshot
Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis
inferredcites →https://doi.org/10.1002/hep.27395openalex-snapshot
The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1007/s00125-005-1682-xopenalex-snapshot
Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms
inferredcites →https://doi.org/10.1007/s11892-007-0029-zopenalex-snapshot
NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes
inferredcites →https://doi.org/10.1007/s40265-012-0004-0openalex-snapshot
Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches
inferredcites →https://doi.org/10.1016/j.cgh.2015.01.027openalex-snapshot
Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1016/j.cmet.2011.11.004openalex-snapshot
Excessive Hepatic Mitochondrial TCA Cycle and Gluconeogenesis in Humans with Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1016/j.cmet.2015.04.004openalex-snapshot
Adaptation of Hepatic Mitochondrial Function in Humans with Non-Alcoholic Fatty Liver Is Lost in Steatohepatitis
inferredcites →https://doi.org/10.1016/j.jhep.2014.08.040openalex-snapshot
Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis
inferredcites →https://doi.org/10.1038/ajg.2010.18openalex-snapshot
Nonalcoholic Fatty Liver Disease Increases Risk of Death Among Patients With Diabetes: A Community-Based Cohort Study
inferredcites →https://doi.org/10.1053/j.gastro.2007.04.068openalex-snapshot
Relationship Between Hepatic/Visceral Fat and Hepatic Insulin Resistance in Nondiabetic and Type 2 Diabetic Subjects
inferredcites →https://doi.org/10.1053/j.gastro.2008.03.021openalex-snapshot
Increased Liver Fat, Impaired Insulin Clearance, and Hepatic and Adipose Tissue Insulin Resistance in Type 2 Diabetes
inferredcites →https://doi.org/10.1053/j.gastro.2010.09.038openalex-snapshot
Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
inferredcites →https://doi.org/10.1053/j.gastro.2012.02.003openalex-snapshot
Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
inferredcites →https://doi.org/10.1056/nejmoa060326openalex-snapshot
A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1097/med.0b013e3283293015openalex-snapshot
Nonalcoholic fatty liver disease in type 2 diabetes mellitus
inferredcites →https://doi.org/10.1097/rmr.0b013e3181c422f1openalex-snapshot
Review of Magnetic Resonance Spectroscopy in the Liver and the Pancreas
inferredcites →https://doi.org/10.1111/j.1478-3231.2008.01718.xopenalex-snapshot
Prevalence and associated factors of non‐alcoholic fatty liver disease in patients with type‐2 diabetes mellitus
inferredcites →https://doi.org/10.1111/liv.12840openalex-snapshot
Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients
inferredcites →https://doi.org/10.1152/ajpendo.1979.237.3.e214openalex-snapshot
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
inferredcites →https://doi.org/10.1172/jci114142openalex-snapshot
Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance.
inferredcites →https://doi.org/10.1210/jc.2014-2739openalex-snapshot
WITHDRAWN: High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels (article published in final form as 10.1210/jc.2015-1966)
inferredcites →https://doi.org/10.1210/jc.2015-1966openalex-snapshot
High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
inferredcites →https://doi.org/10.1210/jc.2015-3111openalex-snapshot
Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD
inferredcites →https://doi.org/10.1210/jc.81.11.4059openalex-snapshot
Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus
inferredcites →https://doi.org/10.2174/138161210791208875openalex-snapshot
Insulin Resistance in Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.2337/db10-1806openalex-snapshot
Liver Enzymes Are Associated With Hepatic Insulin Resistance, Insulin Secretion, and Glucagon Concentration in Healthy Men and Women
inferredcites →https://doi.org/10.2337/dc06-2247openalex-snapshot
Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients
inferredcites →https://doi.org/10.2337/dc10-2229openalex-snapshot
Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study
inferredcites →https://doi.org/10.2337/dc11-1849openalex-snapshot
Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
inferredcites →https://doi.org/10.2337/dc15-s005openalex-snapshot
2. Classification and Diagnosis of Diabetes
inferredcites →https://doi.org/10.2337/diabetes.49.5.749openalex-snapshot
Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients.
inferredcites →https://doi.org/10.2337/diabetes.52.10.2461openalex-snapshot
A Sustained Increase in Plasma Free Fatty Acids Impairs Insulin Secretion in Nondiabetic Subjects Genetically Predisposed to Develop Type 2 Diabetes

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4840179openalex-extracted
The Pan-PPAR Agonist Lanifibranor Reverses Metabolic Dysfunction in People with Type 2 Diabetes and MASLD: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
inferred← citeshttps://doi.org/10.2139/ssrn.4841348openalex-extracted
Zuogui-Jiangtang-Qinggan Formula Alleviated Hepatic Steatosis in Diabetes by Improving Energy and Bile Acid Metabolism: Based on Multi-Omics Integration Studies
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2026.0762openalex-snapshot
Liver Stiffness Measurement and All-Cause Mortality in Individuals With Diabetes
inferred← citeshttps://doi.org/10.1002/edm2.112openalex-snapshot
The metabolic basis of nonalcoholic steatohepatitis
inferred← citeshttps://doi.org/10.1002/edm2.163openalex-snapshot
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review
inferred← citeshttps://doi.org/10.1002/hep.28985openalex-snapshot
Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1002/hep4.1036openalex-snapshot
Treating fatty liver disease by modulating mitochondrial pyruvate metabolism
inferred← citeshttps://doi.org/10.1002/hep4.1077openalex-snapshot
Characteristics of hepatic insulin‐sensitive nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1002/iub.1991openalex-snapshot
Role of vitamin E in nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1007/978-3-319-61013-9_4openalex-snapshot
Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes
inferred← citeshttps://doi.org/10.1007/978-94-007-7675-3_35openalex-snapshot
Hepatic Biomarkers in Diabetes as Modulated by Dietary Phytochemicals
inferred← citeshttps://doi.org/10.1007/978-94-007-7742-2_35-1openalex-snapshot
Hepatic Biomarkers in Diabetes as Modulated by Dietary Phytochemicals
inferred← citeshttps://doi.org/10.1007/s00125-016-3952-1openalex-snapshot
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions
inferred← citeshttps://doi.org/10.1007/s00535-018-1472-0openalex-snapshot
Hepatic IRS1 and ß-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients
inferred← citeshttps://doi.org/10.1007/s00592-019-01374-xopenalex-snapshot
Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients
inferred← citeshttps://doi.org/10.1007/s10522-022-09996-5openalex-snapshot
Metabolic and physical function are improved with lifelong 15% calorie restriction in aging male mice
inferred← citeshttps://doi.org/10.1007/s11739-022-03139-xopenalex-snapshot
NAFLD as the metabolic hallmark of obesity
inferred← citeshttps://doi.org/10.1007/s11892-020-01349-1openalex-snapshot
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1007/s11901-019-00497-7openalex-snapshot
Should We Screen High-Risk Populations for NAFLD?
inferred← citeshttps://doi.org/10.1007/s12020-020-02186-8openalex-snapshot
Relation of adipose tissue insulin resistance to prediabetes
inferred← citeshttps://doi.org/10.1007/s40496-016-0098-7openalex-snapshot
“Non-modifiable” Risk Factors for Periodontitis and Diabetes
inferred← citeshttps://doi.org/10.1007/s40496-016-0099-6openalex-snapshot
Modifiable Risk Factors for Periodontitis and Diabetes
inferred← citeshttps://doi.org/10.1016/b978-0-12-821617-0.00011-5openalex-snapshot
Understanding human diet, disease, and insulin resistance: scientific and evolutionary perspectives
inferred← citeshttps://doi.org/10.1016/b978-2-294-74646-8.00019-5openalex-snapshot
Diabète de type2 etdyslipidémie
inferred← citeshttps://doi.org/10.1016/j.ajg.2018.08.003openalex-snapshot
Managing diabetes and liver disease association
inferred← citeshttps://doi.org/10.1016/j.cellsig.2024.111478openalex-snapshot
Sirt1-mediated deacetylation of PGC-1α alleviated hepatic steatosis in type 2 diabetes mellitus via improving mitochondrial fatty acid oxidation
inferred← citeshttps://doi.org/10.1016/j.cld.2025.04.003openalex-snapshot
The Liver in Diabetes and Metabolic Syndrome
inferred← citeshttps://doi.org/10.1016/j.cpcardiol.2023.101816openalex-snapshot
Nonalcoholic Fatty Liver Disease Predicts Acute Kidney Injury Readmission in Heart Failure Hospitalizations: A Nationwide Analysis
inferred← citeshttps://doi.org/10.1016/j.ecl.2016.06.005openalex-snapshot
Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1016/j.eprac.2022.03.010openalex-snapshot
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
inferred← citeshttps://doi.org/10.1016/j.hbpd.2018.06.004openalex-snapshot
Compromised nutritional status in patients with end-stage liver disease: Role of gut microbiota
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2025.146453openalex-snapshot
Alginate/derivatives and their nanoparticles as anti-diabetic therapeutic via cancer, gut, liver and blood health modulation: A review
inferred← citeshttps://doi.org/10.1016/j.immuni.2024.01.009openalex-snapshot
Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis
inferred← citeshttps://doi.org/10.1016/j.jep.2016.10.039openalex-snapshot
Entada phaseoloides extract suppresses hepatic gluconeogenesis via activation of the AMPK signaling pathway
inferred← citeshttps://doi.org/10.1016/j.jff.2023.105879openalex-snapshot
Integrating network analysis and experimental validation to reveal the mechanism of pinocembrin in alleviating high glucose and free fatty acid-induced lipid accumulation in HepG2 cells
inferred← citeshttps://doi.org/10.1016/j.jhep.2019.10.023openalex-snapshot
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
inferred← citeshttps://doi.org/10.1016/j.jhep.2024.12.045openalex-snapshot
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
inferred← citeshttps://doi.org/10.1016/j.jhepr.2021.100262openalex-snapshot
Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank
inferred← citeshttps://doi.org/10.1016/j.jhepr.2024.101092openalex-snapshot
Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants
inferred← citeshttps://doi.org/10.1016/j.lfs.2026.124534openalex-snapshot
Inflammation-mediated diabetes-liver disease cross-organ crosstalk: From molecular mechanisms to precision therapeutic strategies
inferred← citeshttps://doi.org/10.1016/j.metabol.2024.156066openalex-snapshot
Metabolic dysfunction-associated steatotic liver disease and urinary system cancers: Mere coincidence or reason for concern?
inferred← citeshttps://doi.org/10.1016/j.numecd.2024.07.019openalex-snapshot
Metabolic dysfunction-associated steatotic liver disease: A pathophysiology and clinical framework to face the present and the future
inferred← citeshttps://doi.org/10.1016/j.nupar.2019.12.005openalex-snapshot
La stéatopathie dysmétabolique ou NASH : faut-il dépister les patients à haut risque atteints de diabète de type 2 ou d’obésité ?
inferred← citeshttps://doi.org/10.1016/j.pcd.2016.12.001openalex-snapshot
Clinical correlates of persistently elevated liver enzymes in type 2 diabetic outpatients
inferred← citeshttps://doi.org/10.1016/s2213-8587(22)00003-1openalex-snapshot
A global view of the interplay between non-alcoholic fatty liver disease and diabetes
inferred← citeshttps://doi.org/10.1038/nrgastro.2016.147openalex-snapshot
NAFLD and diabetes mellitus
inferred← citeshttps://doi.org/10.1038/s41387-021-00174-zopenalex-snapshot
Fetuin-B, a potential link of liver-adipose tissue cross talk during diet-induced weight loss–weight maintenance
inferred← citeshttps://doi.org/10.1038/s41440-022-01161-2openalex-snapshot
Fatty liver index predicts the development of hypertension in a Japanese general population with and without dysglycemia
inferred← citeshttps://doi.org/10.1038/s41574-021-00507-zopenalex-snapshot
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1038/s41574-022-00675-6openalex-snapshot
Macrophage functional diversity in NAFLD — more than inflammation
inferred← citeshttps://doi.org/10.1038/s41575-020-00366-5openalex-snapshot
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
inferred← citeshttps://doi.org/10.1039/d3fo05665aopenalex-snapshot
Effect of short-term moderate intake of ice wine on hepatic glycolipid metabolism in C57BL/6J mice
inferred← citeshttps://doi.org/10.1055/a-2266-1503openalex-snapshot
The Pathophysiological Associations Between Obesity, NAFLD, and Atherosclerotic Cardiovascular Diseases
inferred← citeshttps://doi.org/10.1080/07853890.2025.2548976openalex-snapshot
Glycemic variability in type 2 diabetic patients with metabolic dysfunction-associated steatotic liver disease: a case-control study
inferred← citeshttps://doi.org/10.1080/13543784.2020.1715940openalex-snapshot
NASH (nonalcoholic steatohepatitis), diabetes, and macrovascular disease: multiple chronic conditions and a potential treatment at the metabolic root
inferred← citeshttps://doi.org/10.1080/13685538.2020.1763293openalex-snapshot
Non-invasive diagnosis of nonalcoholic fatty liver disease: impact of age and other risk factors
inferred← citeshttps://doi.org/10.1089/met.2022.0105openalex-snapshot
Serum C1q/TNF-Related Protein 4 Levels are Associated with Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients
inferred← citeshttps://doi.org/10.1097/hep.0000000000000263openalex-snapshot
Diabetes and cirrhosis: Current concepts on diagnosis and management
inferred← citeshttps://doi.org/10.1097/hep.0000000000000323openalex-snapshot
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1097/hep.0000000000000710openalex-snapshot
Hyperinsulinemia, an overlooked clue and potential way forward in metabolic dysfunction–associated steatotic liver disease
inferred← citeshttps://doi.org/10.1097/md.0000000000023506openalex-snapshot
Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain
inferred← citeshttps://doi.org/10.1097/meg.0000000000002767openalex-snapshot
Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease
inferred← citeshttps://doi.org/10.1097/mol.0000000000000361openalex-snapshot
Diabetes medications improve cardiovascular outcomes: the paradigm shifts
inferred← citeshttps://doi.org/10.1111/dom.12744openalex-snapshot
Basal insulin peglispro: Overview of a novel long‐acting insulin with reduced peripheral effect resulting in a hepato‐preferential action
inferred← citeshttps://doi.org/10.1111/dom.12751openalex-snapshot
Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes
inferred← citeshttps://doi.org/10.1111/dom.13584openalex-snapshot
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
inferred← citeshttps://doi.org/10.1111/dom.70553openalex-snapshot
Metabolic liver disease: A summary of major guidelines and identifying opportunities to improve future guidelines
inferred← citeshttps://doi.org/10.1111/jdi.14066openalex-snapshot
Association between hemoglobin glycation index and non‐alcoholic fatty liver disease in the patients with type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1111/jphp.12705openalex-snapshot
Influence of hyperglycemia on liver inflammatory conditions in the early phase of non-alcoholic fatty liver disease in mice
inferred← citeshttps://doi.org/10.1136/bmjdrc-2020-001990openalex-snapshot
Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
inferred← citeshttps://doi.org/10.1136/gutjnl-2019-319104openalex-snapshot
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
inferred← citeshttps://doi.org/10.1152/ajpendo.00294.2023openalex-snapshot
Metabolic-associated fatty liver disease is characterized by a post-oral glucose load hyperinsulinemia in individuals with mild metabolic alterations
inferred← citeshttps://doi.org/10.1155/2023/6603522openalex-snapshot
Rhinacanthin C Ameliorates Insulin Resistance and Lipid Accumulation in NAFLD Mice via the AMPK/SIRT1 and SREBP‐1c/FAS/ACC Signaling Pathways
inferred← citeshttps://doi.org/10.1155/2024/6815993openalex-snapshot
Effects of Moringa oleifera Leaf Extract on Liver Histopathology: A Systematic Review
inferred← citeshttps://doi.org/10.1159/000520419openalex-snapshot
Effects of Weight Loss on Adipose and Muscular Neuropilin 1 mRNA Expression in Obesity: Potential Implication in SARS-CoV-2 Infections?
inferred← citeshttps://doi.org/10.11606/d.5.2020.tde-01022021-105744openalex-snapshot
Efeito do treinamento físico na doença hepática gordurosa não alcoólica (DHGNA) em camundongos obesos: aspectos relacionados com a inflamação e resistência insulínica
inferred← citeshttps://doi.org/10.1172/jci.insight.92564openalex-snapshot
Involvement of the metabolic sensor GPR81 in cardiovascular control
inferred← citeshttps://doi.org/10.1177/8756479319834927openalex-snapshot
Sonographic Features of the Liver Among Females With Type 2 Diabetes
inferred← citeshttps://doi.org/10.1186/s12872-025-05137-1openalex-snapshot
Association of weight-adjusted waist index with all-cause and cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease: a national population-based cohort study
inferred← citeshttps://doi.org/10.1186/s12876-022-02550-0openalex-snapshot
Association between hepatic steatosis and fibrosis with measures of insulin sensitivity in patients with severe obesity and type 2 diabetes - a cross-sectional study
inferred← citeshttps://doi.org/10.1186/s12916-016-0638-yopenalex-snapshot
No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
inferred← citeshttps://doi.org/10.1186/s12933-022-01691-6openalex-snapshot
The association of fatty liver index and BARD score with all-cause and cause-specific mortality in patients with type 2 diabetes mellitus: a nationwide population-based study
inferred← citeshttps://doi.org/10.1186/s12944-020-01421-5openalex-snapshot
Association between the non-HDL-cholesterol to HDL-cholesterol ratio and non-alcoholic fatty liver disease in Chinese children and adolescents: a large single-center cross-sectional study
inferred← citeshttps://doi.org/10.1186/s13578-022-00836-0openalex-snapshot
Novel insights into non-alcoholic fatty liver disease and dementia: insulin resistance, hyperammonemia, gut dysbiosis, vascular impairment, and inflammation
inferred← citeshttps://doi.org/10.1194/jlr.m068395openalex-snapshot
Nicotinic acid timed to feeding reverses tissue lipid accumulation and improves glucose control in obese Zucker rats[S]
inferred← citeshttps://doi.org/10.1210/clinem/dgaa753openalex-snapshot
Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood
inferred← citeshttps://doi.org/10.1210/clinem/dgac624openalex-snapshot
Approach to the Patient With Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1210/clinem/dgad249openalex-snapshot
Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS
inferred← citeshttps://doi.org/10.1210/clinem/dgag042openalex-snapshot
Severity of MASH activity by iron-corrected MRI predicts insulin resistance and cardiometabolic risk in type 2 diabetes
inferred← citeshttps://doi.org/10.1210/er.2018-00141openalex-snapshot
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
inferred← citeshttps://doi.org/10.1210/jc.2017-02751openalex-snapshot
Increased Plasma Proneurotensin Levels Identify NAFLD in Adults With and Without Type 2 Diabetes
inferred← citeshttps://doi.org/10.1210/jc.2019-00970openalex-snapshot
Letter to the Editor: “Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content“
inferred← citeshttps://doi.org/10.1210/js.2017-00257openalex-snapshot
Nonalcoholic Fatty Liver Disease in Hispanic Youth With Dysglycemia: Risk for Subclinical Atherosclerosis?
inferred← citeshttps://doi.org/10.12968/gasn.2019.17.2.30openalex-snapshot
Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes: a close and developing relationship
inferred← citeshttps://doi.org/10.14740/jem937openalex-snapshot
Epidemiology of Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes Mellitus and Effects of Antiglycemic Therapy on Liver Fibrosis: A Retrospective Study
inferred← citeshttps://doi.org/10.1530/eje-18-0009openalex-snapshot
MANAGEMENT OF ENDOCRINE DISEASE: Which metabolic procedure? Comparing outcomes in sleeve gastrectomy and Roux-en Y gastric bypass
inferred← citeshttps://doi.org/10.17116/dokgastro20251403156openalex-snapshot
Opportunities of combination therapy for chronic liver diseases: results of the multicenter PROMETHEUS study
inferred← citeshttps://doi.org/10.17925/ee.2024.20.2.2openalex-snapshot
Metabolic Dysfunction-associated Steatotic Liver Disease and Type 2 Diabetes: A Deadly Synergy
inferred← citeshttps://doi.org/10.20517/mtod.2025.32openalex-snapshot
Management of metabolic dysfunction and cardiovascular risk in patients with MASLD
inferred← citeshttps://doi.org/10.2147/dmso.s291350openalex-snapshot
Adipose Tissue Insulin Resistance is Closely Associated with Metabolic Syndrome in Northern Chinese Populations
inferred← citeshttps://doi.org/10.2147/dmso.s349153openalex-snapshot
Association of Circulating TXNIP Levels with Fatty Liver in Newly Diagnosed Type 2 Diabetes Mellitus
inferred← citeshttps://doi.org/10.2174/1573399816999201103141216openalex-snapshot
Hepatic Mediators of Lipid Metabolism and Ketogenesis: Focus on Fatty Liver and Diabetes
inferred← citeshttps://doi.org/10.2174/1573402116999201209203534openalex-snapshot
Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
inferred← citeshttps://doi.org/10.2174/1871530318666181116111945openalex-snapshot
Diabetes Association with Liver Diseases: An Overview for Clinicians
inferred← citeshttps://doi.org/10.2174/1874467215666211217120448openalex-snapshot
Potential Natural Compounds for the Prevention and Treatment of Nonalcoholic Fatty Liver Disease: A Review on Molecular Mechanisms
inferred← citeshttps://doi.org/10.2337/dc16-1787openalex-snapshot
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action
inferred← citeshttps://doi.org/10.2337/dc17-1349openalex-snapshot
Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients
inferred← citeshttps://doi.org/10.2337/dci24-0094openalex-snapshot
Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
inferred← citeshttps://doi.org/10.2337/dsi23-0013openalex-snapshot
Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care
inferred← citeshttps://doi.org/10.26724/2079-8334-2018-1-63-61-64openalex-snapshot
DETERMINATION OF FIBER DEVELOPMENT OF LIVER IN PATIENTS WITH TYPE 2 DIABETES MELLITUS ASSOCIATED WITH NON-ALCOHOL FATTY LIVER DISEASE
inferred← citeshttps://doi.org/10.31032/ijbpas/2021/10.12.1007openalex-snapshot
NON-ALCOHOLIC FATTY LIVER DISEASE IN DIABETIC AND NONDIABETIC PATIENTS
inferred← citeshttps://doi.org/10.32469/10355/93980openalex-snapshot
Lifestyle treatment in the regression of NASH: insulin resistance, lipid synthesis, and methodological innovation
inferred← citeshttps://doi.org/10.3389/fendo.2023.1247611openalex-snapshot
Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1195699openalex-snapshot
Macrophages and the development and progression of non-alcoholic fatty liver disease
inferred← citeshttps://doi.org/10.3389/fmed.2026.1756998openalex-snapshot
PCSK9 inhibitors improve lipid profile and hepatic steatosis surrogate indicators in patients with MAFLD and type 2 diabetes
inferred← citeshttps://doi.org/10.3389/fphar.2022.863839openalex-snapshot
Chinese Herbal Medicine for Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.3389/fphys.2022.909518openalex-snapshot
Extracellular Vesicles in Pathogenesis and Treatment of Metabolic Associated Fatty Liver Disease
inferred← citeshttps://doi.org/10.3390/cells15151377openalex-snapshot
Adipose Tissue Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.3390/children11030275openalex-snapshot
Glucagon-like Peptide-1 Receptor Agonists—A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)
inferred← citeshttps://doi.org/10.3390/gastroent14030027openalex-snapshot
A Current Approach to Non-Alcoholic Steatohepatitis in Type 2 Diabetes Mellitus Patients
inferred← citeshttps://doi.org/10.3390/ijms22010218openalex-snapshot
The Role of Isoflavones in Type 2 Diabetes Prevention and Treatment—A Narrative Review
inferred← citeshttps://doi.org/10.3390/ijms22126627openalex-snapshot
The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart
inferred← citeshttps://doi.org/10.3390/ijms222011128openalex-snapshot
The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.3390/jcm14082750openalex-snapshot
Metabolic Syndrome and Liver Disease: Re-Appraisal of Screening, Diagnosis, and Treatment Through the Paradigm Shift from NAFLD to MASLD
inferred← citeshttps://doi.org/10.3390/life13122317openalex-snapshot
Postprandial Dysmetabolism and Its Medical Implications
inferred← citeshttps://doi.org/10.3390/metabo13050650openalex-snapshot
Dietary Coated Sodium Butyrate Ameliorates Hepatic Lipid Accumulation and Inflammation via Enhancing Antioxidative Function in Post-Peaking Laying Hens
inferred← citeshttps://doi.org/10.3390/molecules25092224openalex-snapshot
Anti-Inflammatory Strategies Targeting Metaflammation in Type 2 Diabetes
inferred← citeshttps://doi.org/10.3390/nu14245339openalex-snapshot
Association between Diet Quality and Index of Non-Alcoholic Steatohepatitis in a Large Population of People with Type 2 Diabetes: Data from the TOSCA.IT Study
inferred← citeshttps://doi.org/10.3390/nu9040387openalex-snapshot
Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments
inferred← citeshttps://doi.org/10.3390/ph19081283openalex-snapshot
Exploring the Molecular Mechanism of Cinnamaldehyde Intervening in Ochratoxin A-Induced Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Comorbidity: An Integrated Approach Based on Network Pharmacology, Network Toxicology and Molecular Docking
inferred← citeshttps://doi.org/10.36290/vnl.2025.005openalex-snapshot
The significance of metabolism-associated steatotic liver disease and its treatment
inferred← citeshttps://doi.org/10.36348/sijap.2023.v06i08.001openalex-snapshot
Waist to Height Ratio a reliable Indicator of Obesity in Igbos of Enugu Metropolis
inferred← citeshttps://doi.org/10.3748/wjg.119898openalex-snapshot
Interplay between cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease: Clinical evidence on cardiovascular disease
inferred← citeshttps://doi.org/10.3748/wjg.v22.i44.9674openalex-snapshot
Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV
inferred← citeshttps://doi.org/10.3892/etm.2017.5400openalex-snapshot
Resveratrol attenuates type 2 diabetes mellitus by mediating mitochondrial biogenesis and lipid metabolism via Sirtuin type 1
inferred← citeshttps://doi.org/10.3892/ijmm.2018.3702openalex-snapshot
Histone modifications in fatty acid synthase modulated by carbohydrate responsive element binding protein are associated with non‑alcoholic fatty liver disease
inferred← citeshttps://doi.org/10.3892/ijmm.2021.4947openalex-snapshot
Role of 2‑series prostaglandins in the pathogenesis of type 2 diabetes mellitus and non‑alcoholic fatty liver disease (Review)
inferred← citeshttps://doi.org/10.4093/dmj.2019.0034openalex-snapshot
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
inferred← citeshttps://doi.org/10.4239/wjd.v14.i5.494openalex-snapshot
Mechanism of immune attack in the progression of obesity-related type 2 diabetes
inferred← citeshttps://doi.org/10.5009/gnl20367openalex-snapshot
Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels
inferred← citeshttps://doi.org/10.5114/aoms/150639openalex-snapshot
Non-alcoholic Fatty Liver Disease, Metabolic syndrome, and Type 2 diabetes mellitus: Where do we stand today?
inferred← citeshttps://doi.org/10.5604/01.3001.0012.0922openalex-snapshot
Impact of Diabetes Mellitus and Insulin on Nonalcoholic Fatty Liver Disease in the Morbidly Obese
inferred← citeshttps://doi.org/10.6084/m9.figshare.26550982openalex-snapshot
Additional file 1 of The association of fatty liver index and BARD score with all-cause and cause-specific mortality in patients with type 2 diabetes mellitus: a nationwide population-based study
inferred← citeshttps://doi.org/10.7150/ijms.62010openalex-snapshot
Association of Hepatic Steatosis Index and Fatty Liver Index with Carotid Atherosclerosis in Type 2 Diabetes
inferred← citeshttps://doi.org/10.7326/m15-1774openalex-snapshot
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.